European Heart Journal Advance Access originally published online on February 21, 2007
European Heart Journal 2007 28(5):522-524; doi:10.1093/eurheartj/ehl555
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Gene expression profile of the recovering human heart
1 Division of Cardiology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
2 Division of Cardiology, University of Rochester Medical Center, Rochester, NY 14642, USA
3 Cardiovascular Research Institute, University of Rochester Medical Center, Rochester, NY 14642, USA
* Corresponding author. Tel: +1 585 273 1094; fax: +1 585 276 1914. E-mail address: burns_blaxall@urmc.rochester.edu
This editorial refers to Molecular signature of recovery following combination left ventricular assist device (LVAD) support and pharmacologic therapy
by J.L. Hall et al., on page 613
| The first 10% of the full text of this article appears below. |
Heart failure is a disease of increasing prevalence and poor prognosis. Current data indicate that 5-year survival following the diagnosis of heart failure is 50%, and patients with end-stage disease face a 1-year survival rate of 50%. Recent predictions suggest that heart failure will become the leading cause of all disability by 2020. For patients with refractory end-stage heart failure, there are few options for effective treatment. Although cardiac transplantation provides the best therapeutic outcome for end-stage HF, substantial limitations of this surgical intervention include an extremely limited supply of acceptable donor hearts, having reached a plateau of less than 3000 per year worldwide.
Left ventricular assist device (LVAD) support of end-stage heart failure patients was originally approved as a bridge to cardiac transplant, and recent reports suggest improved outcomes in
![]()
CiteULike
Connotea
Del.icio.us What's this?
Related articles in EHJ:
- Molecular signature of recovery following combination left ventricular assist device (LVAD) support and pharmacologic therapy
- Jennifer L. Hall, Emma J. Birks, Suzanne Grindle, Martin E. Cullen, Paul J. Barton, James E. Rider, Sangjin Lee, Subash Harwalker, Ami Mariash, Neeta Adhikari, Nathan J. Charles, Leanne E. Felkin, Sean Polster, Robert S. George, Leslie W. Miller, and Magdi H. Yacoub
EHJ 2007 28: 613-627.[Abstract] [FREE Full Text]
This article has been cited by other articles:
![]() |
M. Saeed, A. Martin, A. Jacquier, M. Bucknor, D. Saloner, L. Do, P. Ursell, H. Su, Y. W. Kan, and C. B. Higgins Permanent Coronary Artery Occlusion: Cardiovascular MR Imaging Is Platform for Percutaneous Transendocardial Delivery and Assessment of Gene Therapy in Canine Model Radiology, November 1, 2008; 249(2): 560 - 571. [Abstract] [Full Text] [PDF] |
||||
